Tenders

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Pyridostigmine (Excluding Retarded Dafo.), (Obg) Atc N07aa02 for the Period January 1St, 2025 - December 31St, 2026

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Clindamycin + Benzoyl Peroxide, (Obg) Atc D10af54 for the Period January 1St, 2025 - December 31St, 2026

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V on Active Ingredients (Medicines) - Vv 80

Open House Drug Discount Agreements Tocilizumab, Atc L04ac07

Open Framework Agreement on Drug Discounts in Accordance with Section 130A Paragraph 8 Sgb V with the Possibility of Joining at any Time, So-Called Approval Model 2025-01

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Dexamethasone (Excluding Implant), (Obg) Atc S01ba01 for the Period January 1St, 2025 - December 31St, 2026

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Allergen Extract from Tree Pollen (Exclusively in the Dafo Pump Solution), Atc V01aa05 F. D. Z. 01.01.25 - 31.12.26

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Sevelamer Hydrochloride, (Obg) Atc V03ae02 for the Period January 1St, 2025 - December 31St, 2026

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Apremilast, (Obo) Atc L04aa32 for the Period January 1St, 2025 - December 31St, 2026

Open House Discount Contracts 2024-02